Last reviewed 2026-04-23 · How we verify

Eslicarbazepine Acetate tablets

Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes neuronal membranes and suppresses post-tetanic potentiation.

Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes neuronal membranes and suppresses post-tetanic potentiation. Used for Partial-onset seizures.

At a glance

Mechanism of action

It works by reducing the frequency and severity of seizures in patients with epilepsy. This is achieved by inhibiting the activity of voltage-gated sodium channels, which are responsible for the rapid depolarization of neurons. By stabilizing neuronal membranes, eslicarbazepine acetate reduces the excitability of neurons and prevents the spread of seizure activity.

Approved indications

• Partial-onset seizures

Common side effects

• Dizziness
• Headache
• Fatigue
• Nausea
• Somnolence

Key clinical trials

• Anti-epileptogenic Effects of Eslicarbazepine Acetate (PHASE2)
• A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers (PHASE1)
• Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine (PHASE1)
• The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin (PHASE1)
• Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy (PHASE3)
• Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures (PHASE3)
• Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures (PHASE3)
• A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.